Medical marijuana certification for patients with sickle cell disease: a report of a single center experience.

ABSTRACT: More than one-third of adults with sickle cell disease (SCD) report using cannabis-based products. Many states list SCD or pain as qualifying conditions for medical marijuana, but there are few data to guide practitioners whether or whom should be certified. We postulated that certifying SCD patients may lead to a reduction in opioid use and/or health care utilization. Furthermore, we sought to identify clinical characteristics of patients who would request this intervention. Retrospective data obtained over the study period included rates of health care and opioid utilization for 6 months before certification and after certification. Patients who were certified but failed to obtain medical marijuana were compared with those who obtained it. Patients who were certified were invited to part

SUBMITTER: Curtis SA 

PROVIDER: S-EPMC7448584 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature